Herren Sebastian C, Karau Melissa J, Koscianski Christina A, Christensen Trace A, Granger Dane, Bergan Nathanial G, Mandrekar Jay, Holmes David R, Patel Robin
Department of Laboratory Medicine and Pathology, Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Biochemistry and Molecular Biology, Microscopy and Cell Analysis Core Facility, Mayo Clinic, Rochester, Minnesota, USA.
Antimicrob Agents Chemother. 2024 Jun 5;68(6):e0005224. doi: 10.1128/aac.00052-24. Epub 2024 May 8.
Phage therapy has not been established in the clinical routine, in part due to uncertainties concerning efficacy and immunogenicity. Here, three rabbits were immunized against staphylococcal phage K to assess viral potency in the presence of immunized serum. Three rabbits received weekly intramuscular injections of ~10 pfu/mL phage K. Phage K-specific IgG formation was measured by an enzyme-linked immunosorbent assay (ELISA); phage inactivation was assessed by calculating K-rates. Using transmission electron microscopy (TEM) and immunogold labeling, antibody binding to phage K was visualized. This was numerically assessed by objective imaging analysis comparing the relative distances of each gold particle to the nearest phage head and tail structure. Immunization led to a strong IgG response, plateauing 7 days after the last phage injection. There was no significant correlation between K-rate and antibody titer over time. TEM showed IgG binding to the head structure of phage K. Image analysis showed a significant reduction in relative distances between antibodies and phage head structures when comparing samples from day 0 and day 28 ( < 0.0001). These results suggest that while individual serum analysis for antibodies against therapeutic phage bears consideration prior to and with prolonged therapy, during phage application, the formation of specific antibodies against phage may only partially explain decreased phage potency in the presence of immunized serum. Instead, other factors may contribute to an individual's "humoral receptiveness" to phage therapy. Future investigations should be directed toward the identification of the humoral factors that have the most significant predictive value on phage potency .
噬菌体疗法尚未纳入临床常规应用,部分原因是其疗效和免疫原性存在不确定性。在此,对三只兔子进行针对葡萄球菌噬菌体K的免疫,以评估在存在免疫血清的情况下病毒的效力。三只兔子每周接受肌肉注射约10 pfu/mL的噬菌体K。通过酶联免疫吸附测定(ELISA)测量噬菌体K特异性IgG的形成;通过计算K值评估噬菌体的失活情况。使用透射电子显微镜(TEM)和免疫金标记,观察抗体与噬菌体K的结合情况。通过客观成像分析比较每个金颗粒到最近的噬菌体头部和尾部结构的相对距离,进行数值评估。免疫导致强烈的IgG反应,在最后一次噬菌体注射后7天达到平稳状态。随着时间的推移,K值与抗体滴度之间没有显著相关性。TEM显示IgG与噬菌体K的头部结构结合。图像分析显示,比较第0天和第28天的样本时,抗体与噬菌体头部结构之间的相对距离显著缩短(<0.0001)。这些结果表明,虽然在治疗前和长期治疗期间考虑对治疗性噬菌体抗体进行个体血清分析,但在噬菌体应用过程中,针对噬菌体的特异性抗体的形成可能只能部分解释在存在免疫血清的情况下噬菌体效力降低的原因。相反,其他因素可能导致个体对噬菌体疗法的“体液接受性”。未来的研究应致力于确定对噬菌体效力具有最显著预测价值的体液因素。